Promega is launching the TarSeer BRETSA Target Engagement System, a live-cell, target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins,…
Forward BIOLABS, in partnership with BioForward Madison, announced today the first round of awardees of the Innovation to Commercialization Pipeline (ICP) program. The awardees from the Madison area include Immuto…
Immuto Scientific and the University of Wisconsin announced recently a collaborative agreement to identify disease-specific novel therapeutic targets in colorectal cancer using Immuto’s proprietary structural surfaceomics platform. “Our work with…
FAR Biotech, a computational drug discovery company using proprietary quantum modeling and deep learning AI to tackle high-impact diseases with significant unmet medical need, announced recently that it has moved…
Immuto Scientific has entered into a research collaboration with an unnamed, U.S.-based multinational animal health company, the company announced today. According to a release, the collaboration is designed to apply…
NorthStar Medical Radioisotopes has been successful in routinely producing non-carrier-added Actinium-225 (Ac-225) using its electron accelerator-based technology, becoming the first in the industry to do so, the company announced recently….
SHINE Technologies announced recently that it acquired Lantheus’ SPECT business, which includes the SPECT manufacturing facility in Massachusetts and its portfolio of diagnostic radiopharmaceuticals. “The nuclear medicine supply chain needs…
BrainXell Therapeutics announced recently preclinical data demonstrating the efficacy of its neuronal therapy called BXT-110 as a potential disease-modifying treatment for Parkinson’s disease. BrainXell Therapeutics is using induced pluripotent stem…
Promega, alongside several research institutions, announced recently the publication of a new study in Nature Communications, highlighting technological advances that may accelerate breakthroughs in precision medicine. According to a release,…
Cellectar Biosciences announced today a multi-year supply agreement with Ionetix Corporation, a full-service radioisotope manufacturer. According to a release, Ionetix will provide Cellectar with a clinical and commercial-scale supply of…
